Norton Rose Fulbright represents Alcon in acquisition of LENSAR

A cross-border team from Norton Rose Fulbright represented global eye care provider Alcon Inc. (SIX/NYSE: ALC) in its merger agreement to acquire LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for cataract treatment. The transaction is anticipated to close in mid-to-late 2025.

Pursuant to the terms of the merger agreement, Alcon will purchase shares of LENSAR for US$14 per share in cash. The transaction also includes an additional non-tradeable contingent value right offering up to US$2.75 per share in cash, conditioned on achievement of certain milestones related to LENSAR’s products. The transaction represents a total consideration of up to approximately US$430 million.

Norton Rose Fulbright’s M&A team was led by partner Scarlet McNellie with associates Caleb Segrest, Jennifer Zhang and Josh Buss (Dallas). Robin Adelstein (New York) and Neely Agin (Washington, DC) led the antitrust team with support from Luke McFarland (Washington, DC), Abraham Chang (Houston), Ian Giles (London) and Marc Waha (Tokyo). 

The transaction received global, multidisciplinary support on employee benefits and tax matters from Alexander Clark, Todd Schroeder and Katherine Oglesby (Dallas), on regulatory matters from Mark Faccenda (Washington, DC), on intellectual property matters from Tom Meaney (Dallas), on compliance matters from Stefan Reisinger (Washington, DC), Sharon Oded, Julia Fleminks, Joost Gille (Amsterdam), and Mai Muto (Brussels), on labor matters from Jamila Mensah (Houston), on real estate matters from Katie Van Dyk and Ridley Holmes (Austin) and on environmental matters from Janet McQuaid (Houston).